Sustained Epigenetic Reactivation in Fragile X Neurons with an RNA-Binding Small Molecule
Genes · 2025
DOI: 10.3390/genes16030278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Christina W Kam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Weill Medical College, Cornell University, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Fragile X Syndrome, Fragile X Messenger Ribonucleoprotein 1, Epigenesis, Genetic, Neurons. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background/Objectives: Fragile X syndrome (FXS) is a disease of pathologic epigenetic silencing induced by RNA. In FXS, an expanded CGG repeat tract in the FMR1 gene induces epigenetic silencing during embryogenesis. FMR1 silencing can be reversed with 5-aza-deoxyctidine (5-aza-dC), a nonspecific epigenetic reactivator; however, continuous administration of 5-aza-dC is problematic due to its toxicity. We describe an approach to restore FMR1 expression in FXS neurons by transient treatment with 5-aza-dC, followed by treatment with 2HE-5NMe, which binds the CGG repeat expansion in the FMR1 mRNA and could block the resilencing of the FMR1 gene after withdrawal of 5-aza-dC.
Methods
This study uses immunofluorescence and fluorescent in situ hybridization (FISH) to measure whether FMR1 expression is maintained in FXS post-mitotic neurons treated with 2HE-5NMe. Genome-wide profiling of histone marks was used to monitor epigenetic changes and drug selectivity in response to 5-aza-dC followed by 2HE-5NMe treatment. Changes to dendritic morphology were visualized using confocal microscopy.
Results
In this study, we find that 2HE-5Nme maintains FMR1 in a reactivated state after reactivation using 5-aza-dC in post-mitotic neurons. FMR1 reactivation in neurons results in the re-expression of FMRP and reversal of FXS-associated dendritic spine defects.
Conclusions
These results demonstrate that an RNA-binding small molecule can achieve gene-specific epigenetic control and provide an approach for the restoration of FMRP in FXS neurons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Weill Medical College, Cornell University, New York, NY 10065, USA.
- The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA.
- Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA.
- Department of Chemistry and Physics, University of Tennessee at Chattanooga, Chattanooga, TN 37403, USA.
- Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA.
- Department of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
ORCID-Profile: Jason G Dumelie, Wang-Yong Yang, Samie R Jaffrey
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- NIH HHS
- NICHD NIH HHS
- NIH
- EMBO long-term postdoctoral fellowship
Zitieren
APA
Kam, C. W., Dumelie, J. G., Ciceri, G., Yang, W. Y., Disney, M. D., Studer, L., & Jaffrey, S. R. (2025). Sustained Epigenetic Reactivation in Fragile X Neurons with an RNA-Binding Small Molecule. Genes. https://doi.org/10.3390/genes16030278
Vancouver
Kam CW, Dumelie JG, Ciceri G, Yang WY, Disney MD, Studer L, et al. Sustained Epigenetic Reactivation in Fragile X Neurons with an RNA-Binding Small Molecule. Genes. 2025. doi:10.3390/genes16030278
BibTeX
@article{Kam2025,
author = {Kam, Christina W and Dumelie, Jason G and Ciceri, Gabriele and Yang, Wang-Yong and Disney, Matthew D and Studer, Lorenz and Jaffrey, Samie R},
title = {Sustained Epigenetic Reactivation in Fragile X Neurons with an RNA-Binding Small Molecule},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16030278}
}
EUVIMED